References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- Erratum: global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;70(4):313.
- Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.
- Zhang L, Cui M, Song L, et al. Function, Significance, and Regulation of Rap1b in Malignancy. Crit Rev Eukaryot Gene Expr. 2019;29(2):151–160.
- Chen WB, Pan HQ, He Y, et al. Rap1b but not Rap1a in the forebrain is required for learned fear. Cell Biosci. 2020;10:107.
- Rho SS, Kobayashi I, Oguri-Nakamura E, et al. Rap1b Promotes Notch-Signal-Mediated Hematopoietic Stem Cell Development by Enhancing Integrin-Mediated Cell Adhesion. Dev Cell. 2019;49(5):681–696.e686.
- Lakshmikanthan S, Sobczak M, Li Calzi S, et al. Rap1B promotes VEGF-induced endothelial permeability and is required for dynamic regulation of the endothelial barrier. J Cell Sci. 2018;131(1):jcs207605.
- Tang Z, Peng H, Chen J, et al. Rap1b enhances the invasion and migration of hepatocellular carcinoma cells by up-regulating Twist 1. Exp Cell Res. 2018;367(1):56–64.
- Wang C, Wu C, Yang Q, Ding M, Zhong J, Zhang CY, Ge J, Wang J, Zhang C. miR-28-5p acts as a tumor suppressor in renal cell carcinoma for multiple antitumor effects by targeting RAP1B. Oncotarget. 2016;7(45):73888–73902.
- Zhou Z, Xu H, Duan Y, et al. MicroRNA‑101 suppresses colorectal cancer progression by negative regulation of Rap1b. Oncol Lett. 2020;20(3):2225–2231.
- Xu JH, Zhao WY, Fang QQ, et al. Long Noncoding RNA LUADT1 Is Upregulated in Melanoma and May Sponge miR-28-5p to Upregulate RAP1B. Cancer Biother Radiopharm. 2020;35(4):307–312.
- Jia Z, Yang Y, Dengyan Z, et al. RAP1B, a DVL2 binding protein, activates Wnt/beta-catenin signaling in esophageal squamous cell carcinoma. Gene. 2017;611::15–20.
- Wang P, Gu J, Wang K, et al. miR-206 inhibits thyroid cancer proliferation and invasion by targeting RAP1B. J Cell Biochem. 2019;120(11):18927–18936.
- Zhou B, Xu J, Chen Y, et al. miR-200b/c-RAP1B axis represses tumorigenesis and malignant progression of papillary thyroid carcinoma through inhibiting the NF-κB/Twist1 pathway. Exp Cell Res. 2020;387(2):111785.
- Li Y, Liu Y, Shi F, et al. Knockdown of Rap1b Enhances Apoptosis and Autophagy in Gastric Cancer Cells via the PI3K/Akt/mTOR Pathway. Oncol Res. 2016;24(5):287–293.
- Wang Z, Song K, Zhao W, et al. Dendritic cells in tumor microenvironment promoted the neuropathic pain via paracrine inflammatory and growth factors. Bioengineered. 2020;11(1):661–678.
- Xie L, Pan Z. Circular RNA circ_0000467 regulates colorectal cancer development via miR-382-5p/EN2 axis. Bioengineered. 2021;12(1):886–897.
- Chu H, Awasthi A, White GC 2nd, et al. Rap1b regulates B cell development, homing, and T cell-dependent humoral immunity. The Journal of Immunology. 2008;181(5):3373–3383.
- Kumar S, Xu J, Kumar RS, et al. The small GTPase Rap1b negatively regulates neutrophil chemotaxis and transcellular diapedesis by inhibiting Akt activation. J Exp Med. 2014;211(9):1741–1758.
- Xu W, Wittchen ES, Hoopes SL, et al. Small GTPase Rap1A/B Is Required for Lymphatic Development and Adrenomedullin-Induced Stabilization of Lymphatic Endothelial Junctions. Arterioscler Thromb Vasc Biol. 2018;38(10):2410–2422.
- Battle A, Brown CD, Engelhardt BE, et al. Genetic effects on gene expression across human tissues. Nature. 2017;550(7675):204–213.
- The TCGA Legacy. Cell. 2018;173(2):281–282.
- Li T, Fan J, Wang B, et al. TIMER: a Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017;77(21):e108–e110. e108-e110. .
- Mizuno H, Kitada K, Nakai K, et al. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009;2(1):18.
- Wang D, Wang Y, Zou X, et al. FOXO1 inhibition prevents renal ischemia–reperfusion injury via cAMP-response element binding protein/PPAR-γ coactivator-1α-mediated mitochondrial biogenesis. Br J Pharmacol. 2020;177(2):432–448.
- Frische EW, Zwartkruis FJ. Rap1, a mercenary among the Ras-like GTPases. Dev Biol. 2010;340(1):1–9.
- Hoshino A, Kim HS, Bojmar L, et al. Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell. 2020;182(4):1044–1061.e1018.
- Han Q, Li J, Xiong J, et al. Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression. J Exp Clin Cancer Res. 2020;39(1):151.
- Onizuka S, Kawakami S, Taniguchi K, et al. Pancreatic carcinogenesis: apoptosis and angiogenesis. Pancreas. 2004;28(3):317–319.
- Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
- Awasthi A, Samarakoon A, Chu H, et al. Rap1b facilitates NK cell functions via IQGAP1-mediated signalosomes. J Exp Med. 2010;207(9):1923–1938.
- Oda SK, Anderson KG, Ravikumar P, et al. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. J Exp Med. 2020;217(12):e20191166.
- Myers RM, Dolan J, Teachey DT. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia. Expert Rev Clin Immunol. 2020;16(10):1029–1042.
- Lan H, Zhang W, Jin K, et al. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. Drug Deliv. 2020;27(1):1248–1262.
- Cai X, Wei B, Li L, et al. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression. Int Immunopharmacol. 2020;88:106858.
- She X, Yu Z, Cui Y, et al. miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells. Med Oncol. 2014;31(4):892.
- She X, Yu Z, Cui Y, et al. miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. Oncol Rep. 2014;32(3):957–964.
- Iyama T, Wilson DM 3rd:. DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst). 2013;12(8):620–636.
- Michailidi C, Papavassiliou AG, Troungos C. DNA repair mechanisms in colorectal carcinogenesis. Curr Mol Med. 2012;12(3):237–246.
- Williams K, Sobol RW. Mutation research/fundamental and molecular mechanisms of mutagenesis: special issue: DNA repair and genetic instability. Mutat Res. 2013;743-744:1–3.
- Richard GF. The Startling Role of Mismatch Repair in Trinucleotide Repeat Expansions. Cells. 2021;10(5):1019.
- Petrelli F, Ghidini M, Ghidini A, et al. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: a Systematic Review and Meta-analysis. JAMA Oncol. 2020;6(7):1068–1071.
- Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet. 1998;19(3):219–220.
- Etoh T, Kanai Y, Ushijima S, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol. 2004;164(2):689–699.
- Nosho K, Shima K, Irahara N, et al. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2009;15(11):3663–3671.
- Peng DF, Kanai Y, Sawada M, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci. 2005;96(7):403–408.
- Fahy J, Jeltsch A, Arimondo PB. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin Ther Pat. 2012;22(12):1427–1442.